Medicine & healthcare

FDA Clears Roche Blood Test for Alzheimer's Detection

Is this a breakthrough in early detection or replete with its own limitations?

Published AUG 25

FDA Clears Roche Blood Test for Alzheimer's Detection

Story

Above: The Roche logo at its French office in Boulogne-Billancourt, France, on July 22. Image credit: Xavier Galiana/AFP/Getty Images

The Facts

The U.S. Food and Drug Administration (FDA) cleared the Elecsys pTau217 blood test, developed jointly by Roche and Eli Lilly, on Monday to identify amyloid pathology linked to Alzheimer's disease in individuals aged 55 and older who show signs of cognitive decline.
Roche
The Wall Street Journal
CNN
It is the second blood test for Alzheimer's that the FDA has accepted, after the federal agency approved the use of Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, created by the Japanese firm Fujirebio, in May 2025.
U.S. Food and Drug Administration
However, according to Roche, the Elecsys pTau217 test is the first of its kind to support rule-in and rule-out assessments of amyloid pathology using identical validated cutoffs across primary and speciality care.
Roche
Roche claimed the test is compatible with more than 4,500 cobas laboratory instruments already installed in U.S. labs, negating the need for new equipment. Labcorp and Quest Diagnostics stated they intend to offer the test through their networks.
Roche
Forbes
The FDA clearance follows the product gaining the CE Mark in Europe in May, signifying that it meets the European Economic Area's safety, health and environmental protection standards, enabling its use across the continent.
Roche
European Commission
Before blood testing, identifying amyloid pathology typically required PET scans or cerebrospinal fluid testing. This comes as the Centers for Disease Control and Prevention estimates that 6.7 million older Americans live with Alzheimer's, a figure projected to double by 2060.
Newsmax
Quartz
CDC

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

The FDA clearance of Roche's Elecsys pTau217 blood test is a genuine breakthrough in Alzheimer's detection, finally giving primary care doctors a simple, affordable tool to catch the disease earlier. With over 75% of dementia cases going undiagnosed, a minimally invasive test that plugs into existing U.S. lab instruments is exactly the kind of scalable solution that can close that gap and get patients answers faster.

Roche

Narrative B

A simple blood test for Alzheimer's sounds great until you realize a positive result doesn't mean someone actually has the disease. After all, less than 25% of asymptomatic people who tested positive developed Alzheimer's over 16 years. Family doctors typically lack the training to explain these caveats, and rushing to test without cognitive evaluation first risks false diagnoses, unnecessary panic and missing underlying causes.

Nature